Home/Filings/4/0001415889-25-003179
4//SEC Filing

ANG ROBERT 4

Accession 0001415889-25-003179

CIK 0001817229other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 9:23 PM ET

Size

42.8 KB

Accession

0001415889-25-003179

Insider Transaction Report

Form 4
Period: 2025-02-03
ANG ROBERT
DirectorPRESIDENT AND CEO
Transactions
  • Tax Payment

    Common Stock

    2025-02-03$1.34/sh3,248$4,352784,239 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03147,2940 total
    Exercise: $2.18Exp: 2030-03-09Common Stock (147,294 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-0351,0600 total
    Exercise: $18.00Exp: 2031-02-04Common Stock (51,060 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03376,0000 total
    Exercise: $8.63Exp: 2032-01-31Common Stock (376,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+376,000376,000 total
    Exercise: $1.34Exp: 2032-01-31Common Stock (376,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+172,500172,500 total
    Exercise: $1.34Exp: 2032-08-31Common Stock (172,500 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03470,0000 total
    Exercise: $2.41Exp: 2034-01-28Common Stock (470,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+470,000470,000 total
    Exercise: $1.34Exp: 2034-01-28Common Stock (470,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+51,06051,060 total
    Exercise: $1.34Exp: 2031-02-04Common Stock (51,060 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+257,500257,500 total
    Exercise: $1.34Exp: 2033-02-05Common Stock (257,500 underlying)
  • Award

    Common Stock

    2025-02-03+137,500921,739 total
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+147,294147,294 total
    Exercise: $1.34Exp: 2030-03-09Common Stock (147,294 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03652,0860 total
    Exercise: $1.90Exp: 2030-08-20Common Stock (652,086 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+652,086652,086 total
    Exercise: $1.34Exp: 2030-08-20Common Stock (652,086 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03172,5000 total
    Exercise: $4.97Exp: 2032-08-31Common Stock (172,500 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2025-02-03257,5000 total
    Exercise: $5.55Exp: 2033-02-05Common Stock (257,500 underlying)
  • Award

    Employee Stock Option (right to buy)

    2025-02-03+825,000825,000 total
    Exercise: $1.34Exp: 2035-02-02Common Stock (825,000 underlying)
Footnotes (12)
  • [F1]Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").
  • [F10]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.
  • [F11]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.
  • [F12]The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date.
  • [F2]Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date.
  • [F3]On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • [F4]On February 4, 2021, the Reporting Person filed a Form 3 which inadvertently reported that this stock option was for 147,293 shares, when in fact it was for 147,294 shares.
  • [F5]Immediately exercisable.
  • [F6]The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.
  • [F7]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 19, 2021, in each case subject to the Reporting Person's continued service as of each such date.
  • [F8]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.
  • [F9]The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Issuer

Vor Biopharma Inc.

CIK 0001817229

Entity typeother

Related Parties

1
  • filerCIK 0001741283

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 9:23 PM ET
Size
42.8 KB